People: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

32.08USD
2 Jul 2015
Change (% chg)

$-0.01 (-0.03%)
Prev Close
$32.09
Open
$32.00
Day's High
$32.20
Day's Low
$31.60
Volume
359,339
Avg. Vol
622,277
52-wk High
$45.45
52-wk Low
$28.26

Search Stocks

Hindman, Andrew 

Mr. Andrew Hindman is Chief Business Development Officer of the Company. Mr. Hindman has held several senior executive level positions in the biopharmaceutical industry, most recently as President, Chief Executive Officer and member of the Board of Tobira Therapeutics, a privately-held biotechnology company. At Tobira, he was responsible for developing a new corporate strategy, building new leadership and operational teams, and raising operating capital. Prior to Tobira, he held senior corporate development and commercial operating positions at Nodality, Onyx Pharmaceuticals and Gilead Sciences. Mr. Hindman holds a B.A. in biochemistry and economics, graduating Phi Beta Kappa from Wesleyan University, and an executive MBA from Columbia University and the University of California Berkeley, Haas School of Business.

Basic Compensation

Total Annual Compensation, USD 476,986
Restricted Stock Awards, USD 1,685,520
Long-Term Incentive Plans, USD --
All Other, USD 3,005,160
Fiscal Year Total, USD 5,167,670

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ron Cohen

4,045,180

Michael Rogers

1,295,070

Andrew Blight

1,484,560

Jane Wasman

2,334,280

Enrique Carrazana

1,663,700

Andrew Hindman

5,167,670
As Of  30 Dec 2014
Search Stocks